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bstract
A series of novel pyrazinamide condensed azetidinones was prepared with pyrazinamide Schiff’s bases and chloroacetylchloride
n the presence of catalytic amounts of 1,4-dioxane and triethylamine. The chemical structures of the synthesized compounds
6a–6m) were confirmed by melting point analysis, TLC, IR, 1H NMR, mass spectrometry, and elemental analysis. The synthesized
ompounds were evaluated for acetyl and butyl cholinesterase inhibitory activities. The compounds showed a range of inhibitory
ctivities that could be categorized as weak, moderate, or high. Compound 6l exhibited potent acetyl and butyl cholinesterase
nhibitory activities, with IC50 values of 0.09 M and 3.3 M, respectively, when compared with the current therapeutic agent
onepezil HCl. Our present study suggests that pyrazinamide condensed azetidinones might be interesting and have potential as
cetyl and butyl cholinesterase inhibitory compounds.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.  Introduction
Alzheimer’s disease (AD) is the leading cause of
dementia among older people [1]. It is a chronic
and progressive neurodegenerative disease that is
neuropathologically characterized by the extracellular
deposition of -amyloid aggregates and intraneuronal
neurofibrillary tangles. Neuronal loss at the affected
regions causes a deficit in the production of the neuro-behalf of Taibah University. This is an open access article under the
transmitter acetylcholine, leading to cortical cholinergic
dysfunction [2]. Based on the cholinergic hypothesis,
acetylcholinesterase inhibitors were developed to sus-
tain or enhance acetylcholine levels. The crucial role
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of cholinesterases in neural transmission makes them
a primary target of a large number of cholinesterase-
inhibiting drugs and toxins [3]. The toxins are useful for
agricultural purposes and for the preparation of novel
drugs, although there is little interest in new toxins [4].
The neuropathology of AD is generally characterized
by the presence of numerous amyloid -peptide (A)
plaques, neurofibrillary tangles (NFT), and degeneration
or atrophy of the basal forebrain cholinergic neurons.
The loss of basal forebrain cholinergic cells results in
a significant reduction in acetylcholine (ACh) levels,
which plays an important role in the cognitive impair-
ment associated with AD [5]. Disruption of cholinergic
transmission in AD has been proven in many clinical
and neuropathological studies [6,7]. A deficit in Ach
and the loss of presynaptic M2 muscarinic and nicotinic
receptors has also been observed [8]. There is also evi-
dence of an interaction between AChE and A, which
participates in plaques and plays an essential role in
AD pathophysiology. AChE constitutes a stable complex
with senile plaque components and may even enhance
the aggregation of A  peptides and amyloid forma-
tion. The neurotoxicity of amyloid components may be
increased by the presence of AChE [9,10]. In contrast to
the overall decrease in AChE in AD brains, at least in
its later stages, the local concentration of AChE around
the plaques increases as the lesions occur [11]. In addi-
tion to hydrolysing ACh, AChE may also be involved in
other functions such as cell proliferation, differentiation,
and responses to various damaging factors including
stress and amyloid formation [12]. Hence, for the most
part, AChE inhibitors enhance ACh concentrations in the
brain and have been introduced to the market for treating
mild-to-moderate AD. Acetylcholinesterase inhibitors
such as donepezil, rivastigmine, and galantamine are
currently the best available pharmacotherapies for AD
patients [13].
The name lactam is given to cyclic amides. In older
nomenclature, the second carbon in an aliphatic car-
boxylic acid is designated as , the third as , and so
on. Thus, a -lactam is a cyclic amide with four atoms
in its ring. The contemporary name for this ring sys-
tem is azetidinone. -Lactam has come to be a generic
descriptor for the penicillin family. The ring ultimately
proved to be the main component of the pharmacophore
[14,15], so the term possesses both medicinal and
chemical significance. Ketene–imine cycloaddition was
reported by Staudinger to be a smooth, well-documented
route to synthesize substituted -lactam derivatives.
In an effort to investigate the suitably of substi-
tuted monocyclic -lactams as a minimum requirement
for biological activity, many scientists have reportedrsity for Science 10 (2016) 643–650
trans-stereo selective syntheses of butadienyl azetidi-
nones and their Diels–Alder cycloaddition [16,17]. This
includes the preparation of a series of Schiff’s bases
and their reaction with dienyl ketene to produce a trans-
azetidinone. This reaction involved the in situ formation
of the ketene and its subsequent addition to the imine
[18,19].
The 2-azetidinone skeleton, otherwise known as the
-lactam ring, has been recognized as a useful building
block in the synthesis of biologically important com-
pounds. Azetindin-2-one derivatives display interesting
biological activities, including antimicrobial [20,21],
antitubercular [22,23], analgesic, anti-inflammatory
[24], chymase inhibitory [25], antitumor [26], and
antinociceptive [27] activities. The chemical structure
of pyrazinamide provides a valuable molecular template
for the development of agents that are able to interact
with a wide variety of biological activities [28]. Hence,
it was thought worthwhile to synthesize new congeners
by incorporating pyrazinamide and azetidinone moieties
into a single molecular framework and to evaluate their
acetyl and butyl cholinesterase inhibitor activities.
2.  Experimental
2.1.  Materials  and  methods
All of the chemicals were supplied by E. Merck
(Germany) and S.D. fine chemicals (India). The melting
points of the synthesized compounds were determined
in open capillaries using a Veego VMP-1 apparatus,
are expressed in ◦C, and are uncorrected. The IR spec-
tra of the compounds were recorded on a Shimadzu
FT-IR spectrometer using the KBR pellet technique
and are expressed in cm−1. 1H NMR spectra were
recorded on a Bruker DRX-300 (300 MHz FT-NMR)
spectrometer using DMSO-d6 as the solvent and TMS
as an internal standard. The chemical shifts were
reported in ppm. Mass spectra were obtained using
a Shimadzu LCMS 2010A with the ESI ionization
technique.
2.2.  Synthesis  of  the  Schiff’s  bases  (3a–3m)
A mixture of equimolar quantities of compound
pyrazinamide [1] (0.01 M) and the appropriate aryl
or heteroaryl aldehyde [2] (0.01 M) were dissolved in
ethanol (95%). The contents were relaxed for a period
of 3 h in a steam bath. The obtained solid was separated
from the ethanol and crystallized. The percent yield for
the compounds was 66–82% and the compounds melted
at 158–204 ◦C. The IR spectra of compounds 3a–3m
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howed strong absorption bands for the carbonyl group
1728 cm−1), aromatic C–H stretching (3210 cm−1), and
romatic C C stretching (1638 and 1520 cm−1). The 1H
MR spectra of compounds 3a–3m  showed a singlet for
he methine protons at 5.6 (1H, N CH–R), a singlet at
.14 (Ar-H), and doublets at 7.31 (Ar-H).
.3.  Synthesis  of  the  azetidinones  (6a–6m)
Triethylamine (0.01 M) in 1,4-dioxane and
hloroacetyl chloride (0.01 M) were added drop-
ise to a solution containing compounds 3a–3m
0.005 M) at room temperature. The reaction mixture
as stirred for 20 min. The mixture was then refluxed
or 4 h in a water bath. The solid obtained after removal
f the 1,4-dioxane was crystallized from ethanol. The
ield, melting point, spectral characterization, and
lemental analysis of the compounds are reported in
ection 2.4.
.4.  Analytical  data
.4.1.  3-Chloro-4-phenyl-1-(pyrazin-2-ylcarbonyl)
zetidin-2-one  (6a)
Colourless amorphous solid; M.P: 223–225 ◦C;
ield = 74%; IR (KBr, cm−1): 3086 (Ar-C–H), 1668
C O, amide), 1718 (C O), 1560 (Ar-C C), 1274
C–N), and 676 (C–Cl); 1H NMR (DMSO-d6) δ: 5.41
s, 1H, –CH–Cl), 5.63 (s, 1H, –N–CH–), 7.06–7.22 (m,
H, Ar-H), 8.85 (d, 2H, Ar-H), and 9.22 (s, 1H, Ar-H);
S (m/z): M+1 calculated 288.05; found 288.09; Cal-
ulated for C14H10ClN3O2: C, 58.45; H, 3.50; and N,
4.61; found C, 58.41; H, 3.55; and N, 14.56.
.4.2. 3-Chloro-4-[(E)-2-phenylethenyl]-
-(pyrazin-2-ylcarbonyl)  azetidin-2-one  (6b)
Colourless amorphous solid; M.P: 241–243 ◦C;
ield = 70%; IR (KBr, cm−1): 3118 (Ar-C–H), 1678
C O, amide), 1722 (C O), 1592 (Ar-C C), 1186
C–N), and 722 (C–Cl); 1H NMR (DMSO-d6) δ: 4.99 (s,
H, –CH–Cl), 5.07 (s, 1H, –N–CH–), 6.22 (s, 1H, Ali-
–H), 6.54 (s, 1H, Ali-C–H), 7.13–7.28 (m, 4H, Ar-H),
.84 (d, 2H, Ar-H), and 9.22 (s, 1H, Ar-H); MS (m/z):
+1 calculated 314.06; found 314.01; Calculated for
16H12ClN3O2: C, 61.25; H, 3.86; and N, 13.39; found
, 61.29; H, 3.60; and N, 13.46.
.4.3. 3-Chloro-4-(2-nitrophenyl)-1-(pyrazin-
-ylcarbonyl)  azetidin-2-one  (6c)
Colourless amorphous solid; M.P: 246–248 ◦C;
ield = 79%; IR (KBr, cm−1): 3192 (Ar-C–H), 1682
C O, amide), 1725 (C O), 1570 (Ar-C C), 1182rsity for Science 10 (2016) 643–650 645
(C–N), and 760 (C–Cl); 1H NMR (DMSO-d6) δ: 5.38 (s,
1H, –CH–Cl), 5.57 (s, 1H, –N–CH–), 7.32–7.38 (d, 2H,
Ar-H), 7.63 (s,1H, Ar-H), 8.09 (s,1H, Ar-H), 8.85 (d, 2H,
Ar-H), and 9.21 (s, 1H, Ar-H); MS (m/z): M+1 calculated
333.03; found 332.97; Calculated for C14H9ClN4O4: C,
50.54; H, 2.73; and N, 16.84; found C, 50.51; H, 2.75;
and N, 16.88.
2.4.4. 3-Chloro-4-(2-chlorophenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6d)
Colourless amorphous solid; M.P: 238–241 ◦C;
Yield = 74%; IR (KBr, cm−1): 3122 (Ar-C–H), 1692
(C O, amide), 1721 (C O), 1510 (Ar-C C), 1176
(C–N), and 712 (C–Cl); 1H NMR (DMSO-d6) δ: 5.40
(s, 1H, –CH–Cl), 5.63 (s, 1H, –N–CH–), 6.98–7.21 (m,
4H, Ar-H), 8.89 (d, 2H, Ar-H), and 9.27 (s, 1H, Ar-H);
MS (m/z): M+1 calculated 322.01; found 322.06; Cal-
culated for C14H9Cl2N3O2: C, 52.20; H, 2.82; and N,
13.04; found C, 52.24; H, 2.87; and N, 13.08.
2.4.5. 3-Chloro-4-(2-hydroxyphenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6e)
Colourless amorphous solid; M.P: 254–256 ◦C;
Yield = 72%; IR (KBr, cm−1): 3142 (Ar-C–H), 1684
(C O, amide), 1726 (C O), 1612 (Ar-C C), 1176
(C–N), and 758 (C–Cl); 1H NMR (DMSO-d6) δ: 4.98
(s, 1H, Ar-OH), 5.42 (s, 1H, –CH–Cl), 5.62 (s, 1H,
–N–CH–), 6.75–6.96 (m, 4H, Ar-H), 8.85 (d, 2H, Ar-
H), and 9.21 (s, 1H, Ar-H); MS (m/z): M+1 calculated
304.04; found 304.09; Calculated for C14H10ClN3O3: C,
55.37; H, 3.32; and N, 13.84; found C, 55.33; H, 3.37;
and N, 13.89.
2.4.6. 3-Chloro-4-(3-nitrophenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6f)
Colourless amorphous solid; M.P: 266–268 ◦C;
Yield = 76%; IR (KBr, cm−1): 3136 (Ar-C–H), 1678
(C O, amide), 1718 (C O), 1584 (Ar-C C), 1178
(C–N), and 774 (C–Cl); 1H NMR (DMSO-d6) δ: 5.44
(s, 1H, –CH–Cl), 5.60 (s, 1H, –N–CH–), 7.49 (d, 2H,
Ar-H), 8.03 (d, 2H, Ar-H), 8.84 (d, 2H, Ar-H), and 9.29
(s, 1H, Ar-H); MS (m/z): M+1 calculated 333.03; found
333.08; Calculated for C14H9ClN4O4: C, 50.54; H, 2.73;
and N, 16.84; found C, 50.59; H, 2.78; and N, 16.80.
2.4.7. 3-Chloro-4-(3-chlorophenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6g)
◦Colourless amorphous solid; M.P: 273–275 C;
Yield = 78%; IR (KBr, cm−1): 3148 (Ar-C–H), 1694
(C O, amide), 1726 (C O), 1567 (Ar-C C), 1186
(C–N), and 784 (C–Cl); 1H NMR (DMSO-d6) δ: 5.44
h Unive646 K. Elumalai et al. / Journal of Taiba
(s, 1H, –CH–Cl), 5.58 (s, 1H, –N–CH–), 6.99–7.18 (m,
4H, Ar-H), 8.86 (d, 2H, Ar-H), and 9.30 (s, 1H, Ar-H);
MS (m/z): M+1 calculated 322.01; found 321.95; Cal-
culated for C14H9Cl2N3O2: C, 52.20; H, 2.82; and N,
13.04; found C, 52.16; H, 2.78; and N, 13.09.
2.4.8. 3-Chloro-4-(4-chlorophenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6h)
Colourless amorphous solid; M.P: 284–286 ◦C;
Yield = 81%; IR (KBr, cm−1): 3156 (Ar-C–H), 1696
(C O, amide), 1722 (C O), 1586 (Ar-C C), 1178
(C–N), and 796 (C–Cl); 1H NMR (DMSO-d6) δ: 5.43
(s, 1H, –CH–Cl), 5.59 (s, 1H, –N–CH–), 7.05–7.27 (m,
4H, Ar-H), 8.83 (d, 2H, Ar-H), and 9.25 (s, 1H, Ar-H);
MS (m/z): M + 1 calculated 322.01; found 322.07; Cal-
culated for C14H9Cl2N3O2: C, 52.20; H, 2.82; and N,
13.04; found C, 52.25; H, 2.87; and N, 13.10.
2.4.9. 3-Chloro-4-(4-ﬂuorophenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6i)
Colourless amorphous solid; M.P: 308–311 ◦C;
Yield = 84%; IR (KBr, cm−1): 3167 (Ar-C–H), 1688
(C O, amide), 1716 (C O), 1584 (Ar-C C), 1176
(C–N), and 774 (C–Cl); 1H NMR (DMSO-d6) δ: 5.49
(s, 1H, –CH–Cl), 5.67 (s, 1H, –N–CH–), 6.90–7.15
(m, 4H, Ar-H), 8.81 (d, 2H, Ar-H), and 9.39 (s,
1H, Ar-H); MS (m/z): M+1 calculated 306.04; found
306.09; Calculated for C14H9ClFN3O2: C, 55.01; H,
2.97; and N, 13.75; found C, 55.07; H, 3.04; and N,
13.81.
2.4.10. 3-Chloro-4-(4-methoxyphenyl)-1-(pyrazin-
2-ylcarbonyl)  azetidin-2-one  (6j)
Colourless amorphous solid; M.P: 276–278 ◦C;
Yield = 82%; IR (KBr, cm−1): 3136 (Ar-C–H), 1694
(C O, amide), 1712 (C O), 1528 (Ar-C C), 1182
(C–N), and 768 (C–Cl); 1H NMR (DMSO-d6) δ: 3.68
(s, 3H, O–CH3) 5.40 (s, 1H, –CH–Cl), 5.64 (s, 1H,
–N–CH–), 6.74–7.07 (m, 4H, Ar-H), 8.86 (d, 2H, Ar-
H), and 9.27 (s, 1H, Ar-H); MS (m/z): M+1 calculated
318.06; found 318.02; Calculated for C15H12ClN3O3: C,
56.70; H, 3.81; and N, 13.23; found C, 56.66; H, 3.86;
and N, 13.28.
2.4.11. 3-Chloro-4-(furan-2-yl)-1-(pyrazin-2-
ylcarbonyl)  azetidin-2-one  (6k)
Colourless amorphous solid; M.P: 227–229 ◦C;
Yield = 74%; IR (KBr, cm−1): 3156 (Ar-C–H), 1686
(C O, amide), 1723 (C O), 1468 (Ar-C C), 1188
(C–N), and 768 (C–Cl); 1H NMR (DMSO-d6) δ: 5.46
(s, 1H, –CH–Cl), 5.82 (s, 1H, –N–CH–), 6.12 (d, 2H,
Ar-H), 7.21 (s, 1H, Ar-H), 8.83 (d, 2H, Ar-H), andrsity for Science 10 (2016) 643–650
9.21 (s, 1H, Ar-H); MS (m/z): M+1 calculated 278.03;
found 278.08; Calculated for C12H8ClN3O3: C, 51.91;
H, 2.90; and N, 15.13; found C, 51.87; H, 2.85; and N,
15.18.
2.4.12. 3-Chloro-1-(pyrazin-2-ylcarbonyl)-4-
(pyridin-4-yl)  azetidin-2-one  (6l)
Colourless amorphous solid; M.P: 308–310 ◦C;
Yield = 79%; IR (KBr, cm−1): 3172 (Ar-C–H), 1694
(C O, amide), 1716 (C O), 1432 (Ar-C C), 1168
(C–N), and 772 (C–Cl); 1H NMR (DMSO-d6) δ: 5.47
(s, 1H, –CH–Cl), 5.59 (s, 1H, –N–CH–), 7.49 (d, 2H,
Ar-H), 8.58 (d, 2H, Ar-H),8.82 (d, 2H, Ar-H), and 9.26
(s, 1H, Ar-H); MS (m/z): M+1 calculated 289.04; found
289.08; Calculated for C13H9ClN4O2: C, 54.09; H, 3.14;
and N, 19.41; found C, 54.04; H, 3.19; and N, 19.45.
2.4.13. 3-Chloro-1-(pyrazin-2-ylcarbonyl)-4-
(pyridin-3-yl)  azetidin-2-one  (6m)
Colourless amorphous solid; M.P: 321–322 ◦C;
Yield = 83%; IR (KBr, cm−1): 3152 (Ar-C–H), 1698
(C O, amide), 1722 (C O), 1522 (Ar-C C), 1186
(C–N), and 766 (C–Cl); 1H NMR (DMSO-d6) δ: 5.44
(s, 1H, –CH–Cl), 5.63 (s, 1H, –N–CH–), 7.72 (d, 2H,
Ar-H), 8.68 (d, 2H, Ar-H),8.83 (d, 2H, Ar-H), and 9.28
(s, 1H, Ar-H); MS (m/z): M+1 calculated 289.04; found
289.08; Calculated for C13H9ClN4O2: C, 54.09; H, 3.14;
and N, 19.41; found C, 54.04; H, 3.19; and N, 19.45.
2.5.  Acetylcholinestrase  inhibitory  activity
2.5.1.  In  vitro  inhibition  studies  on  AChE  and
BuChE
Acetylcholinesterase (AChE, from electric eel),
butyl cholinesterase (BuChE, from equine serum),
5,5′-dithiobis-(2-nitrobenzoic acid) (Ellman’s reagent,
DTNB), acetylthiocholine chloride (ATC), butyl thio-
choline chloride (BTC), and hydrochloride were
purchased from Sigma–Aldrich. The azetidinones
were dissolved in DMSO and diluted in 0.1 M
KH2PO4/K2HPO4 buffer (pH 8.0) to the final concen-
tration range. DMSO was diluted to a concentration in
excess of 1 in 10,000, and no inhibitory action on either
AChE or BuChE was detected in separate prior experi-
ments.
2.5.2. In  vitro  AChE  assay
All of the assays were carried out in 0.1 MKH2PO4/K2HPO4 buffers at pH 8.0 using a Shimadzu
UV-2450 spectrophotometer. Enzyme solutions were
prepared at a concentration of 2.0 units/mL in 2-
mL aliquots. The assay media (1 mL) consisted of
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hosphate buffer (pH 8.0), 50 L of 0.01 M DTNB,
0 L of enzyme, and 50 L of 0.01 M substrate (ACh
hloride solution). Test compounds were added to the
ssay solution and pre-incubated at 37 ◦C with the
nzyme for 15 min followed by the addition of the sub-
trate. The activity was determined by measuring the
ncrease in absorbance at 412 nm at 1-min intervals at
7 ◦C. Calculations were performed according to Ell-
an’s method [29]. Each concentration was assayed in
riplicate. The in vitro assay used to test BuChE was
imilar to the method used for AChE.
.  Results  and  discussion
A series of 13 novel and biologically interesting
yrazinamide condensed azetidinone derivatives were
ynthesized and evaluated for their acetyl and butyl
holinesterase inhibitory activities. All of the com-
ounds were purified and analyzed by IR, 1H NMR, MS,
nd elemental analysis of their structures.
.1.  Chemistry
Synthesis of azetidinone derivatives by adopting con-
ensation reaction was performed by following the steps
utlined in Fig. 1. In the first step, the Schiff base was
ynthesized by reacting pyrazinamide with chloroacetyl
hloride in the presence of triethylamine and 1,4-dioxane
nder net conditions. The reaction time was 4.0 h. In
N
N
NH2
O
+ RCHO a
1 2
Fig. 1. Reagents and conditions: (a) 95% of ethanol, reflux 3 hrsity for Science 10 (2016) 643–650 647
total, 13 compounds (6a–6m), including various sub-
stituted azetidinone derivatives, were synthesized with
yields ranging from 70% to 84%. These conditions allow
this method to be applicable for the synthesis of azetidi-
nones from heterocyclic compounds. The azetidinones
were synthesized relatively easily using triethylamine in
1-dioxane as an efficient catalyst.
The azetidinones were prepared via the Staudinger
reaction. In this reaction, the ketene and imine molecules
can act as either nucleophiles or electrophiles (Fig. 2).
In the first step, the imine adds to the ketene as a
nucleophile. The zwitterionic intermediate undergoes
a stepwise ring closure to give the -lactam ring. The
stereoselectivity is generated from the competition
between the direct ring closure and the isomerization
of the imine moiety in the zwitterionic intermediate.
The ring closure step is most likely an intramolecular
nucleophilic addition of the enolate to the imine moiety,
which is obviously affected by the electronic effect of
the ketene and imine substituents. Electron-donating
ketene substituents and electron-withdrawing imine
substituents accelerate the direct ring closure, leading
to a preference for cis--lactam formation. In con-
trast, electron-withdrawing ketene substituents and
electron-donating imine substituents slow the direct
ring closure, leading to a preference for trans--lactam
formation [30]. The IR spectra of compounds 6a–6m
showed strong absorption bands for aromatic C–H
stretching (3086–3192 cm−1), aromatic C C stretching
N
N
N
O
R
+
Cl
O
Cl
b
N
N
O
N
O
Cl
R
3a-m
6a-m
, (b) triethylamine, 1,4-dioxane, stir-20 min, reflux 4 h.
648 K. Elumalai et al. / Journal of Taibah University for Science 10 (2016) 643–650
ism of SFig. 2. General mechan
(1432–1612 cm−1), amide C O (1668–1692 cm−1),
carbonyl C O (1712–1726 cm−1), C–N groups
(1168–1274 cm−1), and C–Cl groups (676–796 cm−1).
The 1H NMR spectra of compounds 6a–6m  showed an
N–CH– group proton singlet (1.84–1.98 ppm), a CH–Cl
proton singlet (2.46–2.72 ppm), an aromatic proton
singlet (7.04–7.14 ppm), an aromatic proton doublet
(7.19–7.38 ppm), and an aromatic proton multiplet
(7.35–7.78 ppm). The mass spectra and elemental
analysis results were within ±0.6% of the theoretical
values. The present protocol best describes the synthesis
of azetidinone derivative compounds, which were novel
and not reported elsewhere.
3.2.  Acetylcholinestrase  inhibitory  activity
The novel substituted azetidinone derivatives (com-
pounds 6a–6m) for treating AD were assayed for
their anti-cholinesterase activities according to Ell-
man’s method on acetylcholinesterase (AChE) from
electric eels using commercial donepezil HCl as the
reference standard. The butyl cholinesterases’ (BuChE)
inhibitory effects on equine serum BuChE were also
examined using the same method. The inhibition
of AChE and BuChE activities by the synthesized
compounds is shown in Fig. 3 and Table 1. The
data listed in Fig. 3 and Table 1 clearly show that
most of the compounds exhibited good to moder-
ate inhibitory activities towards AChE and BuChE.
All of the azetidinone derivatives were potent AChEtaudinger azetidinones.
and BuChE inhibitors, with IC50 values ranging from
micromolar to submicromolar. Compound 6l showed
the best AChE and BuChE inhibitory activities of all
of the azetidinone derivatives, with IC50 values of
0.09 M and 3.3 M, respectively. Among the com-
pounds reported herein, compound 6l  is arguably the
most potent.
3.3.  Structure–activity  relationship
By analysing the activities of the synthesized com-
pounds, the following structure–activity relationships
(SAR) were obtained. The N1 position of the azetidi-
none derivatives contains a pyrazinamide group that
contributes to the activity against acetylcholinesterase
and butyl cholinesterase. The pyrazinamide ring system
was found to be the structural portion of the phar-
macophore, as almost all of the compounds possessed
this substructure. The differences in the bioactivi-
ties of the azetidinones could be correlated to the
substituents at the 4th position. The fourth position
of the azetidinone contains the aryl, heteroaryl or
substituted aryl group that is responsible for acetyl-
choline esterase and butyl cholinesterase inhibitory
potency (Fig. 2 and Table 1). Among the reported
compounds, compound 6l  contained a 4-pyridyl group
at the azetidinone 4th position and showed potent
acetylcholinesterase and butyl cholinesterase inhibitory
activities when compared with the chloro-, fluoro-,
nitro-, and hydroxyl-substituted phenyl groups at the
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Fig. 3. In vitro cholinesterase enzyme inhibitor activity of synthesized compounds (6a–6m) and Donepezil HCl.
Table 1
Synthesized azetidinones: In vitro cholinesterase enzyme inhibitor activity. General structure of azetidinones
N
N
O
N
O
Cl
R
.
S. No Compound R AChE
IC50 (M) ± SEM
BuChE
IC50 (M) ± SEM
1 6a Phenyl 5.4 ± 0.01 7.2 ± 0.01
2 6b Cinnamyl 4.7 ± 0.01 6.4 ± 0.01
3 6c 2-Nitrophenyl 2.66 ± 0.01 6.2 ± 0.01
4 6d 2-Chlorophenyl 2.54 ± 0.01 6.9 ± 0.01
5 6e 2-Hydroxyphenyl 1.57 ± 0.01 5.5 ± 0.01
6 6f 3-Nitro phenyl 1.86 ± 0.01 5.7 ± 0.02
7 6g 3-Chlorophenyl 1.72 ± 0.01 5.1 ± 0.01
8 6h 4-Chlorophenyl 0.6 ± 0.01 4.1 ± 0.01
9 6i 4-Flurophenyl 0.3 ± 0.01 3.9 ± 0.01
10 6j 4-Methoxyphenyl 1.91 ± 0.01 4.8 ± 0.01
11 6k 2-Furyl 5.6 ± 0.01 6.8 ± 0.01
12 6l 4-Pyridyl 0.09 ± 0.01 3.3 ± 0.01
1
1
s
p
m
i
s
o
p
l
g
c
o3 6m 3-Pyridyl 
4 Donepezil HCl Standard 
ame position. Incorporation of a para-substituted
henyl ring at the azetidinone 4th position showed
oderate acetylcholinesterase and butyl cholinesterase
nhibitory activities compared with ortho- and meta-
ubstituted phenyl rings at the same position. The order
f reactivity for the compounds containing substituted
henyl rings at the azetidinone 4th position is as fol-
ows: F > Cl > NO2 > OH > H. The unsubstituted phenyl
roup 6a  showed weaker acetylcholinesterase and butyl
holinesterase inhibitor activities when compared to
ther compounds.0.14 ± 0.01 3.7 ± 0.01
0.12 ± 0.01 3.4 ± 0.01
4.  Conclusions
A series of novel and biologically interesting pyraz-
inamide condensed azetidinones were synthesized and
structurally analyzed. The azetidinones were prepared
using triethylamine in 1,4-dioxane as an efficient
catalyst. The importance of substitutions at the aze-
tidinone fourth positions was studied by examining
acetylcholinesterase and butyl cholinesterase inhibitory
activities. Almost all of the compounds exhibited
weak, moderate, or high acetylcholinesterase and butyl
h Unive
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cholinesterase inhibitory activities. Among the com-
pounds reported herein, compound 6l  is arguably the
most potent. Our study suggests that this is an interest-
ing compound in comparison with the current therapeutic
agent donepezil HCl and should be considered a candi-
date for further investigation.
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